<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Uterine tissue extraction by morcellation: Techniques and clinical issues</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Uterine tissue extraction by morcellation: Techniques and clinical issues</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Uterine tissue extraction by morcellation: Techniques and clinical issues</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth A Stewart, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Goff, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tommaso Falcone, MD, FRCSC, FACOG</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 14, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2910248764"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Gynecologic surgery often employs tissue extraction techniques to remove a large specimen (uterus or leiomyomas) through a small incision. A common tissue extraction technique is morcellation (cutting a specimen into small pieces). Initially, morcellation was only performed using a scalpel at the time of vaginal procedures or laparotomy. As laparoscopic and robotic techniques were adopted, there was the advent of electromechanical morcellators that utilize rapidly rotating blades to quickly core and remove specimens through the small incisions utilized for these procedures. In 2014, concerns were raised that morcellation may disseminate tumor cells in cases in which an undiagnosed uterine malignancy was present. This prompted action by the US Food and Drug Administration (FDA), resulting in new guidelines for the use of electromechanical morcellators and a subsequent decrease in use of these devices [<a href="#rid1">1-7</a>].</p><p>Uterine morcellation techniques are reviewed here. General principles of the treatment of leiomyomas are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5478.html" rel="external">"Uterine fibroids (leiomyomas): Treatment overview"</a> and  <a class="medical medical_review" href="/z/d/html/14195.html" rel="external">"Uterine fibroids (leiomyomas): Open abdominal myomectomy procedure"</a> and  <a class="medical medical_review" href="/z/d/html/15780.html" rel="external">"Uterine fibroids (leiomyomas): Laparoscopic myomectomy and other laparoscopic treatments"</a>.)</p><p class="headingAnchor" id="H1202053956"><span class="h1">TERMINOLOGY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Morcellation – Cutting tissue into small pieces. This is typically performed to remove a large tissue specimen through a small incision.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Electromechanical morcellation – Morcellation of tissue with an electric device. This is usually used only in laparoscopic or robotic procedures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Scalpel morcellation – Morcellation of tissue using a scalpel; the specimen is cut into fewer and larger pieces, which are less likely to be distributed throughout the abdomen or left in the abdomen after surgery compared with electromechanical morcellation. In gynecologic surgery, this is typically done to remove a bulky uterine specimen during vaginal hysterectomy and sometimes during a myomectomy or hysterectomy through a minilaparotomy incision.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intraperitoneal morcellation – Tissue morcellation is performed within the peritoneal cavity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extraperitoneal morcellation – A type of scalpel morcellation in which the specimen is grasped and brought to the intraperitoneal side of a minilaparotomy incision. It is then partially exteriorized (ie, the specimen is grasped on the other side and pulled through the incision so that it is extraperitoneal). The extraperitoneal part is then excised, and the process is repeated until the entire specimen has been removed. This has also been termed extracorporeal morcellation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In-bag containment system – Intraperitoneal bag used in laparoscopic surgery; morcellation is performed within bag.</p><p></p><p class="headingAnchor" id="H479668437"><span class="h1">CLINICAL APPLICATIONS</span><span class="headingEndMark"> — </span>Tissue morcellation is performed in gynecologic surgery when a large tissue specimen must be removed through a small incision. This is done to facilitate less invasive surgical approaches, including vaginal or laparoscopic surgery. Morcellation is most commonly performed when the preoperative diagnosis is uterine fibroids because of the extensive uterine enlargement characteristic of this disease. The gynecologic procedures that typically use morcellation include:</p><p class="bulletIndent1"><span class="glyph">●</span>Laparoscopic hysterectomy – When total laparoscopic hysterectomy is performed, the uterus may be morcellated or removed via the vaginal incision. Depending on the size of the uterus, the specimen may be removed intact or may require scalpel morcellation. Subtotal laparoscopic hysterectomy requires morcellation, however, and since there is no vaginal incision morcellation, it typically occurs through an abdominal incision.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laparoscopic myomectomy – Removal of uterine leiomyomas (fibroids), with removal typically through an abdominal incision.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vaginal hysterectomy – If the uterine specimen is too large to remove via the vaginal incision, scalpel morcellation is performed.</p><p></p><p>Use of morcellation in other surgical specialties is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4874.html" rel="external">"Instruments and devices used in laparoscopic surgery", section on 'Morcellators'</a>.)</p><p class="headingAnchor" id="H1348906413"><span class="h1">RISKS OF MORCELLATION</span><span class="headingEndMark"> — </span>Use of uterine morcellation raises several concerns, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Dissemination of tissue – If an unsuspected malignancy is present, morcellated uterine tissue may result in spillage and spread of cancer cells, thus leading to an advanced stage and potentially a worsened prognosis. This is of particular concern with electromechanical morcellators, since use of these devices results in multiple tissue fragments, and the rotational force of the device may distribute the fragments around the peritoneal cavity. However, scalpel morcellation or any other type of disruption of uterine tissue (supracervical hysterectomy, myomectomy) may lead to tissue spread. Dissemination of tissue can also occur with nonmalignant tissues, such as endometriosis and myomas. (See  <a class="medical medical_review" href="/z/d/html/14203.html" rel="external">"Uterine fibroids (leiomyomas): Differentiating fibroids from uterine sarcomas", section on 'Do techniques that disrupt a mass disseminate tissue and worsen prognosis?'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Disruption of the tissue specimen for pathology evaluation – Morcellated tissue is in fragments; thus, gross pathology, relationship of fragments to each other and the uterus, and margins are not clear, and pathologic evaluation may be difficult. Morcellation impacts the ability to determine specimen size and renders problematic determining depth of invasion of carcinoma (if present) and presence of circumscription (eg, in order to distinguish endometrial stromal nodule from endometrial stromal sarcoma).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surgical complications – Electromechanical morcellators must be used carefully to avoid injury to adjacent structures.</p><p></p><p class="headingAnchor" id="H225584146"><span class="h2">Tissue dissemination and worsened prognosis</span><span class="headingEndMark"> — </span>The main concern regarding uterine morcellation is the dissemination of tissue in patients operated on for presumed benign leiomyomas who are found postoperatively to have uterine sarcoma or other malignancy. This is a clinical challenge since leiomyomas are very common (female lifetime prevalence of 70 to 80 percent) and are difficult to differentiate preoperatively from uterine sarcoma, which is a rare and aggressive malignancy. In addition, patients with no uterine mass who undergo surgery for benign indications may have an unsuspected uterine cancer. The concern regarding morcellation has broadened beyond dissemination of uterine sarcomas to encompass dissemination of other benign and malignant lesions from intraperitoneal morcellation (leiomyoma variants and endometrial carcinoma).</p><p class="headingAnchor" id="H2872946855"><span class="h3">Uterine sarcoma</span><span class="headingEndMark"> — </span>In studies and systematic reviews of patients undergoing hysterectomy or myomectomy for presumed benign leiomyomas, the prevalence of sarcoma is approximately 0.20 percent (1 in 500) in most studies or reviews, and estimates of the prevalence range from 0.05 (1 in 2000) to 0.28 percent (1 in 352) depending upon which studies are included or excluded [<a href="#rid8">8-23</a>]. The majority of cases are leiomyosarcoma, a highly aggressive cancer, but there are also reports of cases of endometrial stromal sarcoma, generally a more indolent cancer. Sarcoma risk increases with increasing age and is higher in postmenopausal patients. (See  <a class="medical medical_review" href="/z/d/html/14203.html" rel="external">"Uterine fibroids (leiomyomas): Differentiating fibroids from uterine sarcomas", section on 'Prevalence of sarcoma in patients undergoing surgery for benign indications'</a>.)</p><p>Morcellation of uterine sarcoma appears to be associated with a worsened prognosis [<a href="#rid19">19,24-31</a>]. However, there are few data, and the available studies often include both scalpel and electromechanical morcellation with hysterectomy or for myomectomy. Most studies are from referral centers, which may include patients with a worse prognosis. Representative studies include:</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of four observational studies in patients with uterine sarcoma found that morcellation (scalpel or power methods) compared with no morcellation was associated with a significantly higher recurrence rate (61 versus 39 percent, odds ratio [OR] 3.16, 95% CI 1.38-7.26) and mortality rate (48 versus 29 percent, OR 2.42, 95% CI 1.19-4.92) [<a href="#rid29">29</a>]. The intra-abdominal recurrence rate was significantly higher in patients who had undergone morcellation compared with other patients, while the extra-abdominal recurrence rate showed a trend toward being higher in patients who had not undergone morcellation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A population-based study of a health care system included 125 hysterectomies with detection of an occult uterine sarcoma [<a href="#rid30">30</a>]. The majority of patients had stage I disease (64 percent). The risk of recurrence was significantly higher in patients who underwent any type of morcellation (power or nonpower) compared with no morcellation (34 versus 21 percent, 2.4-fold higher at one year and 62 versus 53 percent, 1.9-fold higher at three years). At one year, the risk of death was significantly higher for any type of morcellation compared with no morcellation (18 versus 5 percent, 4.8-fold) and for electromechanical morcellation compared with nonelectromechanical morcellation (25 versus 16 percent, 5.1-fold).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective cohort study of 30 patients with uterine sarcoma diagnosed postoperatively who underwent myomectomy with morcellation (power or scalpel morcellation) were compared with patients who underwent total hysterectomy [<a href="#rid31">31</a>]. At five years, patients in the myomectomy with morcellation group had a significantly lower overall survival rate (38 versus 43 percent); no statistically significant difference was found in recurrence-free survival (24 versus 46 percent), but the trend was toward a lower rate with myomectomy and morcellation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective study included in the analysis of patients with uterine sarcoma confined to the uterus at presentation (19 had intraperitoneal scalpel or electromechanical morcellation; 38 had total abdominal hysterectomy) found that morcellation was associated with a significant decrease in the median time to recurrence (10.8 versus 39.6 months) [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective study of patients with uterine leiomyosarcoma compared those who did or did not undergo morcellation [<a href="#rid32">32</a>]. Patients in the morcellation group (n = 15) had no statistically significant difference in five-year overall survival (76 versus 55 percent) or recurrence-free survival (64 versus 43 percent), although there was a trend toward a worse prognosis with morcellation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective study of patients with incidentally diagnosed sarcomas following uterine-sparing surgery followed by re-exploration (n = 15) and staging was compared with patients undergoing hysterectomy as the primary procedure (n = 30) [<a href="#rid33">33</a>]. Thirty-six percent of the patients having uterine-sparing procedures were found to have residual seromas, and none had disseminated disease. There was no difference in progression-free survival over a median of 41 months between the two modes of surgery with re-exploration.</p><p></p><p class="headingAnchor" id="H1856145825"><span class="h3">Leiomyoma variants</span><span class="headingEndMark"> — </span>In addition to uterine sarcoma, there is concern about morcellation of uterine smooth muscle tumors of uncertain malignant potential (STUMP) and disseminated growth of ordinary leiomyoma implants [<a href="#rid34">34,35</a>]. In a systematic review that included 39 studies of morcellation and leiomyoma variants, the risk of parasitic myoma was 0.9 percent and there were rare reports of cases that resembled disseminated peritoneal leiomyomatosis [<a href="#rid36">36</a>]. Several other studies of patients with STUMP who underwent morcellation and then had a subsequent surgical re-exploration have reported that most patients have smooth muscle peritoneal implants [<a href="#rid15">15,37,38</a>]. (See  <a class="medical medical_review" href="/z/d/html/15676.html" rel="external">"Uterine fibroids (leiomyomas): Variants and smooth muscle tumors of uncertain malignant potential"</a>.)</p><p>There is also concern about benign fibroids being iatrogenically spread via uncontained electromechanical morcellation (eg, resembling disseminated peritoneal and/or retroperitoneal leiomyomatosis, parasitic myomas), which may require additional surgical intervention [<a href="#rid39">39-41</a>].</p><p class="headingAnchor" id="H730282876"><span class="h3">Endometrial carcinoma</span><span class="headingEndMark"> — </span>Endometrial carcinoma or hyperplasia is typically diagnosed preoperatively since endometrial sampling is a simple and effective diagnostic method and should be performed in all patients preoperatively, if indicated  (<a class="graphic graphic_table graphicRef58600" href="/z/d/graphic/58600.html" rel="external">table 1</a>). However, unsuspected endometrial carcinoma is occasionally diagnosed postoperatively, particularly in asymptomatic patients and in those who undergo hysterectomy for indications other than abnormal uterine bleeding (eg, pelvic organ prolapse) [<a href="#rid42">42-45</a>].</p><p class="headingAnchor" id="H1726033325"><span class="h3">Other conditions</span><span class="headingEndMark"> — </span>Other conditions may be disseminated by morcellation. These include endometriosis or adenomyosis [<a href="#rid46">46</a>]. In a systematic review that included 11 studies regarding these conditions following morcellation, there was a 1.4 percent risk of spread of endometriosis and 0.6 percent risk for adenomyosis [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H650247852"><span class="h2">Surgical complications</span><span class="headingEndMark"> — </span>There are few data regarding the frequency of power morcellator injuries. While injuries do occur, there is no evidence that this type of device is associated with a higher than acceptable visceral or vascular injury rate. In a study of the US Food and Drug Administration (FDA) device databases between 1993 and 2013, there were 55 surgical complications involving electromechanical morcellators reported; 21 were bowel injuries and 27 were vascular [<a href="#rid34">34</a>].</p><p>Rates of complications may be higher when a containment bag is used. In a retrospective study including over 37,000 patients undergoing laparoscopic supracervical hysterectomy with power morcellation in the United States from 2010 to 2018, those performed with (6 percent) versus without a containment bag had higher rates of short-term surgical complications (4.5 versus 3.3 percent, adjusted relative risk 1.35, 95% CI 1.12-1.64) [<a href="#rid7">7</a>]. The study had several limitations, including that all complications (ie, surgical and medical) that occurred during the index hospitalization were included in this analysis. Furthermore, the preoperative indication for surgery was not known, which is critical in the decision-making for morcellation as well as containment bag use. </p><p class="headingAnchor" id="H1458064048"><span class="h2">Power versus scalpel morcellation</span><span class="headingEndMark"> — </span>Most studies that have evaluated the risks of morcellation include data from both power and scalpel morcellation.</p><p>Studies that examined scalpel morcellation alone include:</p><p class="bulletIndent1"><span class="glyph">●</span>One study included patients who underwent vaginal or laparoscopic-assisted vaginal hysterectomy (n = 1629) [<a href="#rid47">47</a>]. Morcellation was performed in 19 percent of patients. Postoperative diagnoses included two sarcomas, three STUMPs, and eight endometrial carcinomas. Among these, only one of the STUMPs was morcellated. The two patients with sarcomas had no evidence of disease at 2 and 16 months, respectively, and the STUMPs had no evidence of disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study of patients who underwent total hysterectomy for presumed benign leiomyomas who were found to have uterine sarcoma included 18 patients, most of whom had transvaginal scalpel morcellation [<a href="#rid48">48</a>]. Follow-up data at 17 to 54 months were available for 15 patients, all of whom had no evidence of disease.</p><p></p><p class="headingAnchor" id="H3994122333"><span class="h2">Other procedures</span><span class="headingEndMark"> — </span>There are no data or guidelines regarding the risk of dissemination of potentially malignant tissue with hysteroscopic morcellation. The risk of this is likely lower since the uterus is mostly contained, although tissue and fluid may extrude from the fallopian tubes. This has been raised as a potential concern when hysteroscopy is used in the evaluation of abnormal uterine bleeding. (See  <a class="medical medical_review" href="/z/d/html/3314.html" rel="external">"Uterine fibroids (leiomyomas): Hysteroscopic myomectomy", section on 'Tissue extraction device'</a> and  <a class="medical medical_review" href="/z/d/html/3278.html" rel="external">"Overview of hysteroscopy", section on 'Dissemination of tumor'</a>.)</p><p class="headingAnchor" id="H1544030385"><span class="h1">POLICY STATEMENTS</span><span class="headingEndMark"> — </span>The risk of a dissemination of malignant cells in patients with an incidental finding of malignancy associated with electromechanical morcellation of uterine tissue has been the focus of review and statements by the US Food and Drug Administration (FDA), American College of Obstetricians and Gynecologists (ACOG), American Association of Gynecologic Laparoscopists (AAGL), Society of Gynecologic Oncology (SGO), European Society for Gynaecological Endoscopy (ESGE), French College of Obstetrics and Gynecology (CNGOF), and German Society for Gynecology and Obstetrics (DGGG) [<a href="#rid8">8,21,49-54</a>]. All of these statements emphasize the importance of several key preoperative steps when morcellation is planned, including appropriate evaluation for uterine and cervical cancer, assessment for uterine sarcoma risk factors, and informed consent regarding the risk of tumor dissemination. In addition, all organizations have acknowledged the need to gather more data regarding the risks of morcellation. However, the limitations on uterine morcellation have been the subject of controversy [<a href="#rid55">55-57</a>].</p><p class="headingAnchor" id="H839278201"><span class="h2">Government agencies</span><span class="headingEndMark"> — </span>In July 2014, the FDA convened a public meeting of the Obstetrics and Gynecology Medical Devices Advisory Committee. Based on this meeting and a review of the use of electromechanical morcellation [<a href="#rid8">8</a>], in November 2014, the FDA published an updated safety communication, which was reaffirmed in December 2020, with the following recommendations [<a href="#rid40">40,58</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Laparoscopic electromechanical morcellators are contraindicated for removal of uterine tissue in patients who are peri- or postmenopausal or are candidates for en bloc tissue removal: for example, through the vagina or minilaparotomy incision. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laparoscopic electromechanical morcellators are contraindicated in gynecologic surgery in which the tissue to be morcellated is known or suspected to contain malignancy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Be aware of the following boxed warning recommended by the FDA: The FDA warns that uterine tissue may contain unsuspected cancer. The use of laparoscopic electromechanical morcellators during fibroid surgery may spread cancer and decrease the long-term survival of patients. This information should be shared with patients when considering surgery with the use of these devices.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Carefully consider all the available treatment options for patients with uterine fibroids.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thoroughly discuss the benefits and risks of all treatments with patients. Be certain to inform the small group of patients for whom laparoscopic electromechanical morcellation may be an acceptable therapeutic option that their fibroid(s) may contain unexpected cancerous tissue and that laparoscopic electromechanical morcellation may spread the cancer, significantly worsening their prognosis. This population might include some younger patients who want to maintain their fertility or patients not yet perimenopausal who wish to keep their uterus after being informed of the risks.</p><p></p><p>The clinical impact of the FDA recommendations appears to be a decrease in laparoscopic procedures [<a href="#rid59">59</a>]. As an example, a survey found that many surgeons are not using electromechanical morcellation, often due to hospital mandate, and laparotomy rates have increased [<a href="#rid60">60</a>]. The majority of survey respondents did not think the recommendations have led to improved patient outcomes, and some thought that they had led to harm.</p><p>In December 2017, the FDA released an updated systematic review of the incidence of uterine sarcoma in patients undergoing surgery for presumed benign fibroids. There was no change in recommendations [<a href="#rid61">61</a>].</p><p>In May 2014, Health Canada issued a statement to hospital leadership regarding use of electric morcellators during laparoscopic hysterectomy and myomectomy with the following recommendations [<a href="#rid62">62</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Recognize the prevalence of unsuspected uterine sarcoma in patients under consideration for hysterectomy or myomectomy for the treatment of uterine fibroids.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Consider the treatment alternatives for patients with symptomatic uterine fibroids, and review these options with each prospective surgical patient. Some surgeons use closed electromechanical or scalpel morcellation in a bag as a way to reduce the risk of inadvertent spread of uterine tissue. Alternative surgical procedures, such as laparotomy, can also be used to avoid the need for morcellation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Be aware and inform patients that laparoscopic electric morcellation of unsuspected uterine sarcoma during hysterectomy or myomectomy may disseminate the disease and negatively impact prognosis.</p><p></p><p class="headingAnchor" id="H4007373420"><span class="h2">Professional societies</span><span class="headingEndMark"> — </span>The 2014 ACOG statement addressed both the risks and benefits of morcellation and was updated in March 2021; the following are excerpts from the revised guideline [<a href="#rid50">50,63</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Preoperative evaluation includes risk stratification and the appropriate use of imaging, cervical cancer screening, and endometrial tissue sampling to identify malignancy, although leiomyosarcoma is not reliably identified preoperatively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The obstetrician-gynecologist and patient should engage in shared decision-making, including informed consent, explaining the risks and benefits of each approach to surgery for presumed leiomyomas, the risks and benefits of morcellation, and alternatives to morcellation.</p><p></p><p>The AAGL statement regarding the FDA safety communication includes the following [<a href="#rid51">51</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The following information needs to be clarified: a specific definition of perimenopausal patients; the role of electromechanical morcellation in the large group of reproductive-age patients who undergo myomectomy for fertility-sparing surgery; use of electromechanical morcellation in patients with nonfibroid uteri who may have refractory uterine bleeding, prolapse, or adenomyosis; guidance regarding the use of containment bags; and guidance regarding the role of nonelectromechanical morcellation (use of a manual cold knife scalpel in vaginal or minilaparotomy tissue extraction).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abandoning electromechanical morcellation technology for many patients undergoing minimally invasive myomectomy, supracervical hysterectomy, or hysterectomy for a large uterus will be a setback in the care of patients with gynecologic conditions. With meticulous adherence to preoperative patient selection guidelines and informed consent, the AAGL believes appropriately performed electromechanical morcellation outweighs the risk of laparotomy in low-risk patients and is an option to be carefully considered by patients and their gynecologists.</p><p></p><p class="headingAnchor" id="H915050877"><span class="h1">PREOPERATIVE EVALUATION</span><span class="headingEndMark"> — </span>Patients planned for gynecologic surgery should undergo assessment for gynecologic cancers, including appropriate screening tests and evaluation of symptoms. This evaluation may not identify all cancers. The detection rate of endometrial carcinoma is high with office endometrial biopsy. However, uterine sarcoma is difficult to differentiate from uterine leiomyomas; thus, morcellation of a malignant tumor may occur even in low-risk patients.</p><p>Counseling of patients with presumed uterine fibroids includes discussion of the risks and benefits of all available treatment options and appropriate assessment for endometrial carcinoma and uterine sarcoma, including evaluation for current disease and risk factors. (See  <a class="medical medical_review" href="/z/d/html/14203.html" rel="external">"Uterine fibroids (leiomyomas): Differentiating fibroids from uterine sarcomas", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/z/d/html/14203.html" rel="external">"Uterine fibroids (leiomyomas): Differentiating fibroids from uterine sarcomas", section on 'Diagnostic methods'</a>.)</p><p class="headingAnchor" id="H2486270269"><span class="h2">Evaluation for uterine cancer</span><span class="headingEndMark"> — </span>A medical history, risk factors for uterine cancer, and presenting symptoms should be elicited. We recommend <strong>not</strong> using electromechanical morcellation of uterine tissue for patients with significant risk factors for uterine sarcoma, including (see  <a class="medical medical_review" href="/z/d/html/14203.html" rel="external">"Uterine fibroids (leiomyomas): Differentiating fibroids from uterine sarcomas", section on 'Risk factors'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Postmenopausal status</p><p class="bulletIndent1"><span class="glyph">●</span>History of ≥2 years of <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> therapy</p><p class="bulletIndent1"><span class="glyph">●</span>History of pelvic irradiation</p><p class="bulletIndent1"><span class="glyph">●</span>History of childhood retinoblastoma</p><p class="bulletIndent1"><span class="glyph">●</span>Personal history of hereditary leiomyomatosis and renal cell carcinoma syndrome</p><p></p><p>In addition, electromechanical morcellation should not be performed if there are preoperative findings suspicious for uterine malignancy. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Pelvic imaging findings suspicious for uterine cancer – This is challenging because there are no reliable imaging findings that are specific for uterine sarcoma. However, magnetic resonance imaging has a high negative predictive value for excluding a sarcoma [<a href="#rid64">64</a>]. (See  <a class="medical medical_review" href="/z/d/html/14203.html" rel="external">"Uterine fibroids (leiomyomas): Differentiating fibroids from uterine sarcomas", section on 'Imaging'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Endometrial sampling findings of endometrial hyperplasia, carcinoma, or uterine sarcoma, or nondiagnostic sampling in patients at high risk of endometrial cancer.</p><p></p><p>All patients undergoing gynecologic surgery should undergo appropriate screening and evaluation preoperatively, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Cervical cancer screening, as appropriate. (See  <a class="medical medical_review" href="/z/d/html/7575.html" rel="external">"Screening for cervical cancer in resource-rich settings"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pelvic imaging, as appropriate for evaluation of abnormal uterine bleeding, pelvic pain, pelvic mass, or surgical planning.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Endometrial sampling for patients with signs, symptoms, or risk factors for endometrial carcinoma or uterine sarcoma  (<a class="graphic graphic_table graphicRef58600" href="/z/d/graphic/58600.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef62089" href="/z/d/graphic/62089.html" rel="external">table 2</a>).</p><p></p><p>Any patient in whom uterine cancer is suspected should be referred to a surgeon with experience in gynecologic oncology procedures and treatment, as appropriate.</p><p>Most, but not all, patients are evaluated with pelvic imaging at some point prior to gynecologic surgery. Endometrial biopsy is not a sensitive test for uterine sarcoma but will detect this condition in up to 60 percent of patients. Since endometrial biopsy is a minimally invasive procedure and is already indicated in many patients with abnormal uterine bleeding to exclude endometrial neoplasia, we suggest sampling in patients in whom sarcoma is suspected or for whom the planned procedure includes intraperitoneal morcellation.</p><p>These measures will likely detect most patients with endometrial carcinoma but will miss many of those with sarcoma, since it is difficult to differentiate sarcoma from benign leiomyomas preoperatively. Differentiating uterine leiomyomas from sarcomas is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/14203.html" rel="external">"Uterine fibroids (leiomyomas): Differentiating fibroids from uterine sarcomas"</a>.)</p><p class="headingAnchor" id="H871268514"><span class="h2">Patient selection</span><span class="headingEndMark"> — </span>Electromechanical morcellation is an option only for <strong>selected premenopausal patients under the age of 50</strong> with uterine fibroids and no significant uterine sarcoma risk factors or clinical features suspicious for other uterine malignancy. For those patients who desire uterine preservation and are candidates for laparoscopic/robotic myomectomy, we offer patients myomectomy with morcellation rather than myomectomy via laparotomy. For those who desire laparoscopic hysterectomy and in whom intact removal of the specimen through the vagina is not possible, we offer laparoscopic hysterectomy with morcellation rather than laparotomy.</p><p>An area of uncertainty regarding morcellation is how to manage perimenopausal patients; the US Food and Drug Administration (FDA) advises against electromechanical morcellation in perimenopausal and postmenopausal patients. The perimenopausal transition can occur over approximately eight years, extending from the time of regular menstrual cycles to the final menstrual period (which is not considered final until one year has passed)  (<a class="graphic graphic_figure graphicRef82933" href="/z/d/graphic/82933.html" rel="external">figure 1</a>). However, there is no evidence that perimenopausal patients are at an increased risk of uterine sarcoma, and in fact there are many patients in this phase who do not know they have entered perimenopause. The principal basis of the increased risk in menopausal patients is that uterine fibroids are unlikely to increase in size or become symptomatic in a hypoestrogenic state, which is not the case during the menopausal transition, during which hormone levels can fluctuate significantly. Thus, we suggest that, for the purpose of this topic, patients be considered perimenopausal if they have significant menstrual irregularity with amenorrhea &gt;60 days, consistent with the late menopausal transition phase. (See  <a class="medical medical_review" href="/z/d/html/7395.html" rel="external">"Clinical manifestations and diagnosis of menopause"</a>.)</p><p>In addition, the FDA advises against electromechanical morcellation in patients who are candidates for en bloc tissue removal (removal of the entire uterus and cervix without any disruption of the specimen). This mainly applies to total hysterectomy, and en bloc tissue removal is preferable whenever possible. It is often possible to do this using a less invasive approach if the uterus is small. In a vaginal hysterectomy or total laparoscopic hysterectomy, the uterus may be able to be removed intact via the vaginal incision.</p><p>However, if intact removal is not possible, then the choice is between morcellation or laparotomy. For patients who have no significant risk factors for uterine sarcoma, use of laparotomy rather than a less invasive approach solely to avoid morcellation may expose patients to higher risks of morbidity and mortality and certainly to a longer recovery period that may affect quality of life [<a href="#rid65">65</a>].</p><p>In addition, for patients who desire uterine preservation, myomectomy using any surgical approach generally involves a great deal of disruption of the specimen(s). If future childbearing is desired, hysterectomy is not an option. There are no data regarding whether laparoscopic myomectomy with electromechanical morcellation or open myomectomy results in a differential risk of tissue dissemination. (See  <a class="medical medical_review" href="/z/d/html/14203.html" rel="external">"Uterine fibroids (leiomyomas): Differentiating fibroids from uterine sarcomas", section on 'Myomectomy'</a>.)</p><p>Patients should be counseled about medical and surgical treatment options. In appropriately selected and counseled patients, if morcellation is an option, patient preference should be a major determining factor regarding whether this is used. Based upon appropriate counseling regarding risks and benefits of morcellation versus laparotomy, the patient can then make an informed choice regarding the surgical approach.</p><p>If a surgical option using electromechanical morcellation is elected, counseling and shared decision-making should include the risk of dissemination of malignant cells if a malignancy is incidentally detected [<a href="#rid49">49,50,66-68</a>]. In cases in which the postoperative pathology shows malignancy, the patient should be referred to a gynecologic oncologist for further evaluation and treatment as soon as possible.</p><p class="headingAnchor" id="H1358691089"><span class="h1">MORCELLATION DEVICES AND TECHNIQUES</span></p><p class="headingAnchor" id="H1364556852"><span class="h2">Power morcellation</span><span class="headingEndMark"> — </span>Electromechanical morcellators use rapidly rotating blades to quickly remove cores of the specimen through small abdominal incisions. With this technology, larger specimens can be removed via laparoscopic or robotic procedures quickly. However, in response to concerns about dissemination of malignant tissue with morcellation (see <a class="local">'Tissue dissemination and worsened prognosis'</a> above), some institutions in the United States have suspended use of power morcellation in patients with uterine masses, and some surgeons have chosen to voluntarily avoid its use [<a href="#rid69">69</a>].</p><p>In an attempt to avoid tumor dissemination, electromechanical morcellation has been performed with the uterine specimen contained and morcellated in a laparoscopic bag  (<a class="graphic graphic_picture graphicRef57113" href="/z/d/graphic/57113.html" rel="external">picture 1</a>) [<a href="#rid70">70-75</a>]. The safety and efficacy of use of a laparoscopic bag for power morcellation require further study. Concerns include:</p><p class="bulletIndent1"><span class="glyph">●</span>Limited ability to visualize the tissue being morcellated and structures outside the bag – This may lead to injury if the bag is penetrated by the morcellator blade; such complications have been reported [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Efficacy of tissue containment – It is controversial whether using a bag adequately contains tissue, including microscopic cells. In addition, if the bag is disrupted by the morcellator blade or by the insertion of ports or instruments, tissue may be disseminated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The use of a containment system may increase procedure duration slightly [<a href="#rid76">76,77</a>].</p><p></p><p>There are no high-quality data regarding electromechanical morcellation containment systems in gynecology. Tissue spread with use of a containment system has been evaluated using pelvic washings or dye. The largest study to evaluate this was a multicenter prospective study of 76 patients who underwent contained electromechanical morcellation for hysterectomy or myomectomy [<a href="#rid78">78</a>]. In this study, the bag had two punctures: one for the morcellator and one for the laparoscope; 5 mL of blue dye was injected into the bag. Spillage of tissue or dye was assessed by gross visualization and was found in 9.2 percent of cases although containment bags were intact. Several smaller clinical studies and an in vitro study have found no leakage of smooth muscle cells or dye [<a href="#rid79">79-81</a>]. A small study of in-bag morcellation via the vaginal incision during total laparoscopic hysterectomy, using a scalpel technique, found ruptures of the bag in 4 of 12 procedures [<a href="#rid82">82</a>].</p><p>An in-bag electromechanical morcellation device (ie, PneumoLiner) using a single port was approved by the US Food and Drug Administration (FDA) in April 2016 [<a href="#rid83">83</a>]. The FDA requires the manufacturer to warn patients and health care providers that PneumoLiner has not been proven to reduce the risk of spreading cancer during these procedures. Other devices and techniques are being developed [<a href="#rid84">84-87</a>].</p><p class="headingAnchor" id="H1041167574"><span class="h2">Scalpel morcellation</span><span class="headingEndMark"> — </span>Scalpel morcellation is the cutting of the uterine specimen into pieces, typically to remove a large uterus during a vaginal hysterectomy. It can be performed with or without a containment system (eg, Alexis Contained Extraction System). Sparse data regarding safety and efficacy are available. In a systematic review of two small trials comparing in-bag scalpel morcellation versus uncontained power morcellation in 176 premenopausal patients undergoing laparoscopic myomectomy, the in-bag group had slightly longer morcellation operative time, but total operating time was similar for both groups [<a href="#rid88">88</a>]. There were no intraoperative complications or leiomyosarcomas in either group.</p><p></p><p>The technique for vaginal hysterectomy is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3308.html" rel="external">"Hysterectomy: Vaginal", section on 'Myometrial coring for intraoperative uterine size reduction'</a>.)</p><p class="headingAnchor" id="H3801786767"><span class="h1">ALTERNATIVE TECHNIQUES</span><span class="headingEndMark"> — </span>Alternatives to electromechanical morcellation include these en bloc resection techniques:</p><p class="bulletIndent1"><span class="glyph">●</span>Intact removal of a specimen using minimally invasive approaches that do not require electromechanical morcellation – These include removing the specimen intact via minilaparotomy or colpotomy (following vaginal hysterectomy or total laparoscopic hysterectomy) [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extracorporeal morcellation, in which a specimen is brought to a minilaparotomy incision or colpotomy and morcellated via the incision – Some experts advise use of a circumferential wound retractor to facilitate this technique [<a href="#rid68">68,89-91</a>]. This may require containing the specimen in an intracorporeal specimen bag to avoid dissemination of tissue [<a href="#rid92">92,93</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laparotomy – This is an option but is associated with a larger incision, more postoperative pain, a longer recovery period, and potentially more complications than minimally invasive approaches [<a href="#rid65">65</a>].</p><p></p><p>In addition, for patients without risk factors for cancer, other nonsurgical alternatives for uterine fibroid treatment include:</p><p class="bulletIndent1"><span class="glyph">●</span>Medical treatments aimed at symptomatic control</p><p class="bulletIndent1"><span class="glyph">●</span>Uterine artery embolization</p><p class="bulletIndent1"><span class="glyph">●</span>Magnetic resonance-guided focused ultrasound</p><p></p><p class="headingAnchor" id="H3586315535"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111091.html" rel="external">"Society guideline links: Uterine fibroids (leiomyomas)"</a>.)</p><p class="headingAnchor" id="H2790234232"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Counseling of patients with presumed uterine fibroids includes discussion of all available treatment options, including the risks and benefits of different surgical approaches. Appropriate preoperative assessment for endometrial carcinoma and uterine sarcoma should be performed, including evaluation for current disease and risk factors. (See <a class="local">'Preoperative evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surgical techniques that disrupt the uterine specimen (scalpel or electromechanical morcellation, supracervical hysterectomy) should <strong>not</strong> be performed in patients with known or suspected uterine or other gynecologic cancer. We recommend <strong>not</strong> using electromechanical morcellation of uterine tissue for patients who have significant risk factors for uterine sarcoma (eg, postmenopausal status, history of ≥2 years of <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> therapy, history of pelvic irradiation, history of childhood retinoblastoma, or personal history of hereditary leiomyomatosis and renal cell carcinoma syndrome) (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>). (See <a class="local">'Preoperative evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For premenopausal patients with uterine fibroids and no significant uterine sarcoma risk factors, based on appropriate counseling and shared decision-making regarding risks and benefits of morcellation versus laparotomy, the patient can then make an informed choice regarding the surgical approach (see <a class="local">'Preoperative evaluation'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those who desire uterine preservation and are candidates for laparoscopic myomectomy, in our practice, we offer patients myomectomy with morcellation as an alternative to myomectomy via laparotomy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those who are not candidates for vaginal hysterectomy and desire laparoscopic hysterectomy and in whom intact removal of the specimen through the vagina is not possible, in our practice, we offer laparoscopic hysterectomy with morcellation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If a surgical option using electromechanical morcellation is elected, counseling should include the risk of dissemination of malignant cells, if a malignancy is incidentally detected. (See <a class="local">'Preoperative evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Electromechanical morcellation devices that have a tissue containment system are available, but their safety, particularly in patients at high risk of uterine cancer, requires further investigation. (See <a class="local">'Power morcellation'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wright JD, Chen L, Burke WM, et al. Trends in Use and Outcomes of Women Undergoing Hysterectomy With Electric Power Morcellation. JAMA 2016; 316:877.</a></li><li><a class="nounderline abstract_t">Hurd WW. On the Road to Safer Morcellation. Obstet Gynecol 2017; 129:976.</a></li><li><a class="nounderline abstract_t">Ottarsdottir H, Cohen SL, Cox M, et al. Trends in Mode of Hysterectomy After the U.S. Food and Drug Administration Power Morcellation Advisory. Obstet Gynecol 2017; 129:1014.</a></li><li><a class="nounderline abstract_t">Stentz NC, Cooney LG, Sammel M, Shah DK. Changes in Myomectomy Practice After the U.S. Food and Drug Administration Safety Communication on Power Morcellation. Obstet Gynecol 2017; 129:1007.</a></li><li><a class="nounderline abstract_t">Zaritsky E, Tucker LY, Neugebauer R, et al. Minimally Invasive Hysterectomy and Power Morcellation Trends in a West Coast Integrated Health System. Obstet Gynecol 2017; 129:996.</a></li><li><a class="nounderline abstract_t">Redberg RF, Jacoby AF, Sharfstein JM. Power Morcellators, Postmarketing Surveillance, and the US Food and Drug Administration. JAMA 2017; 318:325.</a></li><li><a class="nounderline abstract_t">Wright JD, Chen L, Melamed A, et al. Containment Bag Use Among Women Who Undergo Hysterectomy With Laparoscopic Power Morcellation. Obstet Gynecol 2022; 140:371.</a></li><li class="breakAll">FDA executive summary: Laparoscopic power morcellation during uterine surgery for fibroids. Available at: https://wayback.archive-it.org/7993/20170113091521/http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/ObstetricsandGynecologyDevices/UCM404148.pdf (Accessed on November 24, 2014).</li><li><a class="nounderline abstract_t">Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 1994; 83:414.</a></li><li><a class="nounderline abstract_t">Leung F, Terzibachian JJ, Gay C, et al. [Hysterectomies performed for presumed leiomyomas: should the fear of leiomyosarcoma make us apprehend non laparotomic surgical routes?]. Gynecol Obstet Fertil 2009; 37:109.</a></li><li><a class="nounderline abstract_t">Leibsohn S, d'Ablaing G, Mishell DR Jr, Schlaerth JB. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol 1990; 162:968.</a></li><li><a class="nounderline abstract_t">Takamizawa S, Minakami H, Usui R, et al. Risk of complications and uterine malignancies in women undergoing hysterectomy for presumed benign leiomyomas. Gynecol Obstet Invest 1999; 48:193.</a></li><li><a class="nounderline abstract_t">Leung F, Terzibachian JJ. Re: "The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma". Gynecol Oncol 2012; 124:172.</a></li><li><a class="nounderline abstract_t">Durand-Réville M, Dufour P, Vinatier D, et al. [Uterine leiomyosarcomas: a surprising pathology. Review of the literature. Six case reports]. J Gynecol Obstet Biol Reprod (Paris) 1996; 25:710.</a></li><li><a class="nounderline abstract_t">Seidman MA, Oduyebo T, Muto MG, et al. Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms. PLoS One 2012; 7:e50058.</a></li><li><a class="nounderline abstract_t">Theben JU, Schellong AR, Altgassen C, et al. Unexpected malignancies after laparoscopic-assisted supracervical hysterectomies (LASH): an analysis of 1,584 LASH cases. Arch Gynecol Obstet 2013; 287:455.</a></li><li><a class="nounderline abstract_t">Sinha R, Hegde A, Mahajan C, et al. Laparoscopic myomectomy: do size, number, and location of the myomas form limiting factors for laparoscopic myomectomy? J Minim Invasive Gynecol 2008; 15:292.</a></li><li><a class="nounderline abstract_t">Hagemann IS, Hagemann AR, LiVolsi VA, et al. Risk of occult malignancy in morcellated hysterectomy: a case series. Int J Gynecol Pathol 2011; 30:476.</a></li><li><a class="nounderline abstract_t">Park JY, Park SK, Kim DY, et al. The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. Gynecol Oncol 2011; 122:255.</a></li><li><a class="nounderline abstract_t">Kamikabeya TS, Etchebehere RM, Nomelini RS, Murta EF. Gynecological malignant neoplasias diagnosed after hysterectomy performed for leiomyoma in a university hospital. Eur J Gynaecol Oncol 2010; 31:651.</a></li><li class="breakAll">Morcellation During Uterine Tissue Extraction. American Association of Gynecologic Laparoscopists. Available at: http://www.aagl.org/wp-content/uploads/2014/05/Tissue_Extraction_TFR.pdf (Accessed on August 08, 2016).</li><li class="breakAll">US Food and Drug Administration (FDA), Obstetrics and Gynecology Devices Advisory Committee. FDA executive summary: Laparoscopic power morcellation during uterine surgery for fibroids, Washington, DC 2014. https://wayback.archive-it.org/7993/20170113091521/http:/www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/ObstetricsandGynecologyDevices/UCM404148.pdf (Accessed on July 10, 2014).</li><li><a class="nounderline abstract_t">Mahnert N, Morgan D, Campbell D, et al. Unexpected gynecologic malignancy diagnosed after hysterectomy performed for benign indications. Obstet Gynecol 2015; 125:397.</a></li><li><a class="nounderline abstract_t">Morice P, Rodriguez A, Rey A, et al. Prognostic value of initial surgical procedure for patients with uterine sarcoma: analysis of 123 patients. Eur J Gynaecol Oncol 2003; 24:237.</a></li><li><a class="nounderline abstract_t">Perri T, Korach J, Sadetzki S, et al. Uterine leiomyosarcoma: does the primary surgical procedure matter? Int J Gynecol Cancer 2009; 19:257.</a></li><li><a class="nounderline abstract_t">George S, Barysauskas C, Serrano C, et al. Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma. Cancer 2014; 120:3154.</a></li><li><a class="nounderline abstract_t">Pritts EA, Parker WH, Brown J, Olive DL. Outcome of occult uterine leiomyosarcoma after surgery for presumed uterine fibroids: a systematic review. J Minim Invasive Gynecol 2015; 22:26.</a></li><li><a class="nounderline abstract_t">Graebe K, Garcia-Soto A, Aziz M, et al. Incidental power morcellation of malignancy: a retrospective cohort study. Gynecol Oncol 2015; 136:274.</a></li><li><a class="nounderline abstract_t">Bogani G, Cliby WA, Aletti GD. Impact of morcellation on survival outcomes of patients with unexpected uterine leiomyosarcoma: a systematic review and meta-analysis. Gynecol Oncol 2015; 137:167.</a></li><li><a class="nounderline abstract_t">Raine-Bennett T, Tucker LY, Zaritsky E, et al. Occult Uterine Sarcoma and Leiomyosarcoma: Incidence of and Survival Associated With Morcellation. Obstet Gynecol 2016; 127:29.</a></li><li><a class="nounderline abstract_t">Gao Z, Li L, Meng Y. A Retrospective Analysis of the Impact of Myomectomy on Survival in Uterine Sarcoma. PLoS One 2016; 11:e0148050.</a></li><li><a class="nounderline abstract_t">Nemec W, Inwald EC, Buchholz S, et al. Effects of morcellation on long-term outcomes in patients with uterine leiomyosarcoma. Arch Gynecol Obstet 2016; 294:825.</a></li><li><a class="nounderline abstract_t">Lee JY, Kim HS, Nam EJ, et al. Outcomes of uterine sarcoma found incidentally after uterus-preserving surgery for presumed benign disease. BMC Cancer 2016; 16:675.</a></li><li><a class="nounderline abstract_t">Milad MP, Milad EA. Laparoscopic morcellator-related complications. J Minim Invasive Gynecol 2014; 21:486.</a></li><li><a class="nounderline abstract_t">Lu B, Xu J, Pan Z. Iatrogenic parasitic leiomyoma and leiomyomatosis peritonealis disseminata following uterine morcellation. J Obstet Gynaecol Res 2016; 42:990.</a></li><li><a class="nounderline abstract_t">Tulandi T, Leung A, Jan N. Nonmalignant Sequelae of Unconfined Morcellation at Laparoscopic Hysterectomy or Myomectomy. J Minim Invasive Gynecol 2016; 23:331.</a></li><li><a class="nounderline abstract_t">Mowers EL, Skinner B, McLean K, Reynolds RK. Effects of morcellation of uterine smooth muscle tumor of uncertain malignant potential and endometrial stromal sarcoma: case series and recommendations for clinical practice. J Minim Invasive Gynecol 2015; 22:601.</a></li><li><a class="nounderline abstract_t">Oduyebo T, Rauh-Hain AJ, Meserve EE, et al. The value of re-exploration in patients with inadvertently morcellated uterine sarcoma. Gynecol Oncol 2014; 132:360.</a></li><li><a class="nounderline abstract_t">Ordulu Z, Dal Cin P, Chong WW, et al. Disseminated peritoneal leiomyomatosis after laparoscopic supracervical hysterectomy with characteristic molecular cytogenetic findings of uterine leiomyoma. Genes Chromosomes Cancer 2010; 49:1152.</a></li><li class="breakAll">Product Labeling for Laparoscopic Power Morcellators. US Food and Drug Administration. Available at: https://www.fda.gov/media/90012/download (Accessed on May 19, 2021).</li><li><a class="nounderline abstract_t">Cerdeira AS, Ismail L, Moore N, et al. Retroperitoneal leiomyomatosis: a benign outcome of power morcellation with potentially serious consequences. Lancet 2022; 399:554.</a></li><li><a class="nounderline abstract_t">Einstein MH, Barakat RR, Chi DS, et al. Management of uterine malignancy found incidentally after supracervical hysterectomy or uterine morcellation for presumed benign disease. Int J Gynecol Cancer 2008; 18:1065.</a></li><li><a class="nounderline abstract_t">Hill AJ, Carroll AW, Matthews CA. Unanticipated uterine pathologic finding after morcellation during robotic-assisted supracervical hysterectomy and cervicosacropexy for uterine prolapse. Female Pelvic Med Reconstr Surg 2014; 20:113.</a></li><li><a class="nounderline abstract_t">Frick AC, Walters MD, Larkin KS, Barber MD. Risk of unanticipated abnormal gynecologic pathology at the time of hysterectomy for uterovaginal prolapse. Am J Obstet Gynecol 2010; 202:507.e1.</a></li><li><a class="nounderline abstract_t">McPencow AM, Erekson EA, Guess MK, et al. Cost-effectiveness of endometrial evaluation prior to morcellation in surgical procedures for prolapse. Am J Obstet Gynecol 2013; 209:22.e1.</a></li><li><a class="nounderline abstract_t">Urman B, Ata B, Arslan T, et al. Parasitic Myomas and an Adenomyoma Obstructing the Ureter After Power Morcellation of Myomas and Endometriotic Nodule Resection. J Obstet Gynaecol Can 2016; 38:362.</a></li><li><a class="nounderline abstract_t">Balgobin S, Maldonado PA, Chin K, et al. Safety of Manual Morcellation After Vaginal or Laparoscopic-assisted Vaginal Hysterectomy. J Minim Invasive Gynecol 2016; 23:542.</a></li><li><a class="nounderline abstract_t">Zhang J, Li T, Zhang J, et al. Clinical Characteristics and Prognosis of Unexpected Uterine Sarcoma After Hysterectomy for Presumed Myoma With and Without Transvaginal Scalpel Morcellation. Int J Gynecol Cancer 2016; 26:456.</a></li><li class="breakAll">SGO Position Statement: Morcellation. Society of Gynecologic Oncology. Available at: https://www.sgo.org/newsroom/position-statements-2/morcellation/ (Accessed on March 10, 2014).</li><li class="breakAll">Statement on Power Morcellation. American College of Obstetricians and Gynecologists. Available at: http://www.acog.org/About-ACOG/News-Room/Statements/2014/ACOG-Statement-on-Power-Morcellation (Accessed on August 08, 2016).</li><li class="breakAll">AAGL response to FDA guidance on use of power morcellation during tissue extraction for uterine fibroids. Available at: https://www.isge.org/2014/11/aagl-response-to-fda-guidance-on-use-of-power-morcellation/ (Accessed on December 02, 2014).</li><li><a class="nounderline abstract_t">Beckmann MW, Juhasz-Böss I, Denschlag D, et al. Surgical Methods for the Treatment of Uterine Fibroids - Risk of Uterine Sarcoma and Problems of Morcellation: Position Paper of the DGGG. Geburtshilfe Frauenheilkd 2015; 75:148.</a></li><li><a class="nounderline abstract_t">Brölmann H, Tanos V, Grimbizis G, et al. Options on fibroid morcellation: a literature review. Gynecol Surg 2015; 12:3.</a></li><li><a class="nounderline abstract_t">de Rochambeau B, Deffieux X, Chene G, et al. Hysterectomy for benign disease: clinical practice guidelines from the French College of Obstetrics and Gynecology. Eur J Obstet Gynecol Reprod Biol 2016; 202:83.</a></li><li><a class="nounderline abstract_t">Parker WH, Kaunitz AM, Pritts EA, et al. U.S. Food and Drug Administration's Guidance Regarding Morcellation of Leiomyomas: Well-Intentioned, But Is It Harmful for Women? Obstet Gynecol 2016; 127:18.</a></li><li><a class="nounderline abstract_t">Wright JD. Electric Power Morcellation in Gynecology: The Path Forward. Obstet Gynecol 2016; 127:7.</a></li><li><a class="nounderline abstract_t">Garry R. Laparoscopic morcellation: an acceptable risk or an Achilles heel? BJOG 2015; 122:458.</a></li><li class="breakAll">UPDATED laparoscopic uterine power morcellation in hysterectomy and myomectomy: FDA safety communication. Available at: http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm424443.htm (Accessed on November 24, 2014).</li><li><a class="nounderline abstract_t">Barron KI, Richard T, Robinson PS, Lamvu G. Association of the U.S. Food and Drug Administration Morcellation Warning With Rates of Minimally Invasive Hysterectomy and Myomectomy. Obstet Gynecol 2015; 126:1174.</a></li><li><a class="nounderline abstract_t">Lum DA, Sokol ER, Berek JS, et al. Impact of the 2014 Food and Drug Administration Warnings Against Power Morcellation. J Minim Invasive Gynecol 2016; 23:548.</a></li><li class="breakAll">Laparoscopic Power Morcellators. US Food and Drug Administration. Available at: https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/SurgeryandLifeSupport/ucm584463.htm?utm_campaign=12%2F14%2F17%20FDA%20Posts%20New%20Information%20about%20Using%20Laparoscopic%20Power%20Morcellators&amp;utm_medium=email&amp;utm_source=Eloqua (Accessed on December 20, 2017).</li><li class="breakAll">Laparoscopic Electric Morcellators: Risk of Spread of Unsuspected Uterine Sarcoma. Health Canada. Available at: http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2014/39409a-eng.php (Accessed on February 25, 2015).</li><li><a class="nounderline abstract_t">Uterine Morcellation for Presumed Leiomyomas: ACOG Committee Opinion, Number 822. Obstet Gynecol 2021; 137:e63.</a></li><li><a class="nounderline abstract_t">Laughlin-Tommaso SK, Stewart EA. Moving Toward Individualized Medicine for Uterine Leiomyomas. Obstet Gynecol 2018; 132:961.</a></li><li><a class="nounderline abstract_t">Nieboer TE, Johnson N, Lethaby A, et al. Surgical approach to hysterectomy for benign gynaecological disease. Cochrane Database Syst Rev 2009; :CD003677.</a></li><li><a class="nounderline abstract_t">Patient safety must be a priority in all aspects of care. Lancet Oncol 2014; 15:123.</a></li><li><a class="nounderline abstract_t">Kho KA, Nezhat CH. Evaluating the risks of electric uterine morcellation. JAMA 2014; 311:905.</a></li><li><a class="nounderline abstract_t">Kho KA, Anderson TL, Nezhat CH. Intracorporeal electromechanical tissue morcellation: a critical review and recommendations for clinical practice. Obstet Gynecol 2014; 124:787.</a></li><li><a class="nounderline abstract_t">Mandato VD, Torricelli F, Pirillo D, et al. Impact of the Food and Drug Administration Safety Communication on the Use of Power Morcellator in Daily Clinical Practice: An Italian Survey. J Minim Invasive Gynecol 2016; 23:206.</a></li><li><a class="nounderline abstract_t">Zuo Z, Zhang L, Leng X, Huang Z. Iron-catalyzed asymmetric hydrosilylation of ketones. Chem Commun (Camb) 2015; 51:5073.</a></li><li><a class="nounderline abstract_t">Serur E, Lakhi N. Laparoscopic hysterectomy with manual morcellation of the uterus: an original technique that permits the safe and quick removal of a large uterus. Am J Obstet Gynecol 2011; 204:566.e1.</a></li><li><a class="nounderline abstract_t">Einarsson JI, Cohen SL, Fuchs N, Wang KC. In-bag morcellation. J Minim Invasive Gynecol 2014; 21:951.</a></li><li><a class="nounderline abstract_t">Cohen SL, Einarsson JI, Wang KC, et al. Contained power morcellation within an insufflated isolation bag. Obstet Gynecol 2014; 124:491.</a></li><li><a class="nounderline abstract_t">Cholkeri-Singh A, Miller CE. Power morcellation in a specimen bag. J Minim Invasive Gynecol 2015; 22:160.</a></li><li><a class="nounderline abstract_t">McKenna JB, Kanade T, Choi S, et al. The Sydney Contained In Bag Morcellation technique. J Minim Invasive Gynecol 2014; 21:984.</a></li><li><a class="nounderline abstract_t">Vargas MV, Cohen SL, Fuchs-Weizman N, et al. Open power morcellation versus contained power morcellation within an insufflated isolation bag: comparison of perioperative outcomes. J Minim Invasive Gynecol 2015; 22:433.</a></li><li><a class="nounderline abstract_t">Winner B, Porter A, Velloze S, Biest S. Uncontained Compared With Contained Power Morcellation in Total Laparoscopic Hysterectomy. Obstet Gynecol 2015; 126:834.</a></li><li><a class="nounderline abstract_t">Cohen SL, Morris SN, Brown DN, et al. Contained tissue extraction using power morcellation: prospective evaluation of leakage parameters. Am J Obstet Gynecol 2016; 214:257.e1.</a></li><li><a class="nounderline abstract_t">Cohen SL, Greenberg JA, Wang KC, et al. Risk of leakage and tissue dissemination with various contained tissue extraction (CTE) techniques: an in vitro pilot study. J Minim Invasive Gynecol 2014; 21:935.</a></li><li><a class="nounderline abstract_t">Rimbach S, Holzknecht A, Schmedler C, et al. First clinical experiences using a new in-bag morcellation system during laparoscopic hysterectomy. Arch Gynecol Obstet 2016; 294:83.</a></li><li><a class="nounderline abstract_t">Ikhena DE, Paintal A, Milad MP. Feasibility of Washings at the Time of Laparoscopic Power Morcellation: A Pilot Study. J Minim Invasive Gynecol 2016; 23:793.</a></li><li><a class="nounderline abstract_t">Solima E, Scagnelli G, Austoni V, et al. Vaginal Uterine Morcellation Within a Specimen Containment System: A Study of Bag Integrity. J Minim Invasive Gynecol 2015; 22:1244.</a></li><li class="breakAll">FDA allows marketing of first-of-kind tissue containment system for use with certain laparoscopic power morcellators in select patients. US Food and Drug Administration. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm494650.htm (Accessed on April 13, 2016).</li><li><a class="nounderline abstract_t">Trivedi PH, Patil SS, Parekh NA, et al. Laparoscopic Morcellation of Fibroid and Uterus In-Bag. J Obstet Gynaecol India 2015; 65:396.</a></li><li><a class="nounderline abstract_t">Aoki Y, Matsuura M, Matsuno T, Yamamoto T. Single-site in-bag morcellation achieved via direct puncture of the pneumoperitoneum cap, a cordless electric morcellator, and a 5-mm flexible scope. Eur J Obstet Gynecol Reprod Biol 2016; 201:126.</a></li><li><a class="nounderline abstract_t">Anapolski M, Panayotopoulos D, Alkatout I, et al. Power morcellation inside a secure endobag: a pilot study. Minim Invasive Ther Allied Technol 2016; 25:203.</a></li><li><a class="nounderline abstract_t">Anapolski M, Panayotopoulos D, Alkatout I, et al. Preclinical safety testing for morcellation and extraction for an endobag with sealable ports: in vitro pilot study. Surg Endosc 2017; 31:494.</a></li><li><a class="nounderline abstract_t">Zullo F, Venturella R, Raffone A, Saccone G. In-bag manual versus uncontained power morcellation for laparoscopic myomectomy. Cochrane Database Syst Rev 2020; 5:CD013352.</a></li><li><a class="nounderline abstract_t">Serur E, Zambrano N, Brown K, et al. Extracorporeal Manual Morcellation of Very Large Uteri Within an Enclosed Endoscopic Bag: Our 5-Year Experience. J Minim Invasive Gynecol 2016; 23:903.</a></li><li class="breakAll">Video recording of laparoscopically assisted myomectomy. Available at: http://links.lww.com/AOG/A547 (Accessed on February 25, 2015).</li><li class="breakAll">Video recording of enclosed transvaginal morcellation of an enlarged uterus after total laparoscopic hysterectomy and bilateral salpingo-oophorectomy. Available at: http://links.lww.com/AOG/A548 (Accessed on August 08, 2016).</li><li><a class="nounderline abstract_t">Favero G, Anton C, Silva e Silva A, et al. Vaginal morcellation: a new strategy for large gynecological malignant tumor extraction: a pilot study. Gynecol Oncol 2012; 126:443.</a></li><li><a class="nounderline abstract_t">Wyman A, Fuhrig L, Bedaiwy MA, et al. A Novel Technique for Transvaginal Retrieval of Enlarged Pelvic Viscera during Minimally Invasive Surgery. Minim Invasive Surg 2012; 2012:454120.</a></li></ol></div><div id="topicVersionRevision">Topic 108246 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27552622" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Trends in Use and Outcomes of Women Undergoing Hysterectomy With Electric Power Morcellation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28486377" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : On the Road to Safer Morcellation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28486371" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Trends in Mode of Hysterectomy After the U.S. Food and Drug Administration Power Morcellation Advisory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28486366" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Changes in Myomectomy Practice After the U.S. Food and Drug Administration Safety Communication on Power Morcellation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28486359" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Minimally Invasive Hysterectomy and Power Morcellation Trends in a West Coast Integrated Health System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28662227" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Power Morcellators, Postmarketing Surveillance, and the US Food and Drug Administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35926199" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Containment Bag Use Among Women Who Undergo Hysterectomy With Laparoscopic Power Morcellation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35926199" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Containment Bag Use Among Women Who Undergo Hysterectomy With Laparoscopic Power Morcellation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8127535" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19200764" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : [Hysterectomies performed for presumed leiomyomas: should the fear of leiomyosarcoma make us apprehend non laparotomic surgical routes?].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2327466" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10545745" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Risk of complications and uterine malignancies in women undergoing hysterectomy for presumed benign leiomyomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21955481" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Re: "The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8991905" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : [Uterine leiomyosarcomas: a surprising pathology. Review of the literature. Six case reports].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23189178" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23053310" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Unexpected malignancies after laparoscopic-assisted supracervical hysterectomies (LASH): an analysis of 1,584 LASH cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18439500" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Laparoscopic myomectomy: do size, number, and location of the myomas form limiting factors for laparoscopic myomectomy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21804400" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Risk of occult malignancy in morcellated hysterectomy: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21565389" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21319509" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Gynecological malignant neoplasias diagnosed after hysterectomy performed for leiomyoma in a university hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21319509" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Gynecological malignant neoplasias diagnosed after hysterectomy performed for leiomyoma in a university hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21319509" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Gynecological malignant neoplasias diagnosed after hysterectomy performed for leiomyoma in a university hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25569001" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Unexpected gynecologic malignancy diagnosed after hysterectomy performed for benign indications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12807231" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prognostic value of initial surgical procedure for patients with uterine sarcoma: analysis of 123 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19396005" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Uterine leiomyosarcoma: does the primary surgical procedure matter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24923260" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25193444" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Outcome of occult uterine leiomyosarcoma after surgery for presumed uterine fibroids: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25740603" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Incidental power morcellation of malignancy: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25462199" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Impact of morcellation on survival outcomes of patients with unexpected uterine leiomyosarcoma: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26646120" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Occult Uterine Sarcoma and Leiomyosarcoma: Incidence of and Survival Associated With Morcellation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26828206" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A Retrospective Analysis of the Impact of Myomectomy on Survival in Uterine Sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27105972" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effects of morcellation on long-term outcomes in patients with uterine leiomyosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27553655" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Outcomes of uterine sarcoma found incidentally after uterus-preserving surgery for presumed benign disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24333632" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Laparoscopic morcellator-related complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27125448" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Iatrogenic parasitic leiomyoma and leiomyomatosis peritonealis disseminata following uterine morcellation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26802909" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Nonmalignant Sequelae of Unconfined Morcellation at Laparoscopic Hysterectomy or Myomectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25596464" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effects of morcellation of uterine smooth muscle tumor of uncertain malignant potential and endometrial stromal sarcoma: case series and recommendations for clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24296345" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The value of re-exploration in patients with inadvertently morcellated uterine sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20842731" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Disseminated peritoneal leiomyomatosis after laparoscopic supracervical hysterectomy with characteristic molecular cytogenetic findings of uterine leiomyoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20842731" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Disseminated peritoneal leiomyomatosis after laparoscopic supracervical hysterectomy with characteristic molecular cytogenetic findings of uterine leiomyoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35123695" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Retroperitoneal leiomyomatosis: a benign outcome of power morcellation with potentially serious consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17986239" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Management of uterine malignancy found incidentally after supracervical hysterectomy or uterine morcellation for presumed benign disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24566217" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Unanticipated uterine pathologic finding after morcellation during robotic-assisted supracervical hysterectomy and cervicosacropexy for uterine prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20452498" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Risk of unanticipated abnormal gynecologic pathology at the time of hysterectomy for uterovaginal prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23545164" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Cost-effectiveness of endometrial evaluation prior to morcellation in surgical procedures for prolapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27208606" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Parasitic Myomas and an Adenomyoma Obstructing the Ureter After Power Morcellation of Myomas and Endometriotic Nodule Resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26802908" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Safety of Manual Morcellation After Vaginal or Laparoscopic-assisted Vaginal Hysterectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26807642" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clinical Characteristics and Prognosis of Unexpected Uterine Sarcoma After Hysterectomy for Presumed Myoma With and Without Transvaginal Scalpel Morcellation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26807642" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Clinical Characteristics and Prognosis of Unexpected Uterine Sarcoma After Hysterectomy for Presumed Myoma With and Without Transvaginal Scalpel Morcellation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26807642" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Clinical Characteristics and Prognosis of Unexpected Uterine Sarcoma After Hysterectomy for Presumed Myoma With and Without Transvaginal Scalpel Morcellation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26807642" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Clinical Characteristics and Prognosis of Unexpected Uterine Sarcoma After Hysterectomy for Presumed Myoma With and Without Transvaginal Scalpel Morcellation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25797958" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Surgical Methods for the Treatment of Uterine Fibroids - Risk of Uterine Sarcoma and Problems of Morcellation: Position Paper of the DGGG.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25774118" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Options on fibroid morcellation: a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27196085" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Hysterectomy for benign disease: clinical practice guidelines from the French College of Obstetrics and Gynecology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26646134" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : U.S. Food and Drug Administration's Guidance Regarding Morcellation of Leiomyomas: Well-Intentioned, But Is It Harmful for Women?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26646139" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Electric Power Morcellation in Gynecology: The Path Forward.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25236787" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Laparoscopic morcellation: an acceptable risk or an Achilles heel?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25236787" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Laparoscopic morcellation: an acceptable risk or an Achilles heel?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26595561" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Association of the U.S. Food and Drug Administration Morcellation Warning With Rates of Minimally Invasive Hysterectomy and Myomectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26827905" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Impact of the 2014 Food and Drug Administration Warnings Against Power Morcellation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26827905" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Impact of the 2014 Food and Drug Administration Warnings Against Power Morcellation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26827905" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Impact of the 2014 Food and Drug Administration Warnings Against Power Morcellation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33595252" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Uterine Morcellation for Presumed Leiomyomas: ACOG Committee Opinion, Number 822.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30130343" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Moving Toward Individualized Medicine for Uterine Leiomyomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19588344" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Surgical approach to hysterectomy for benign gynaecological disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24480553" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Patient safety must be a priority in all aspects of care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24504415" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Evaluating the risks of electric uterine morcellation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25198260" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Intracorporeal electromechanical tissue morcellation: a critical review and recommendations for clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26454195" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Impact of the Food and Drug Administration Safety Communication on the Use of Power Morcellator in Daily Clinical Practice: An Italian Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25712676" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Iron-catalyzed asymmetric hydrosilylation of ketones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21752759" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Laparoscopic hysterectomy with manual morcellation of the uterus: an original technique that permits the safe and quick removal of a large uterus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24769447" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : In-bag morcellation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25162248" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Contained power morcellation within an insufflated isolation bag.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25460317" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Power morcellation in a specimen bag.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25048565" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The Sydney Contained In Bag Morcellation technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25452122" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Open power morcellation versus contained power morcellation within an insufflated isolation bag: comparison of perioperative outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26348168" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Uncontained Compared With Contained Power Morcellation in Total Laparoscopic Hysterectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26348384" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Contained tissue extraction using power morcellation: prospective evaluation of leakage parameters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24928740" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Risk of leakage and tissue dissemination with various contained tissue extraction (CTE) techniques: an in vitro pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26690354" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : First clinical experiences using a new in-bag morcellation system during laparoscopic hysterectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27068277" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Feasibility of Washings at the Time of Laparoscopic Power Morcellation: A Pilot Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26205578" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Vaginal Uterine Morcellation Within a Specimen Containment System: A Study of Bag Integrity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26205578" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Vaginal Uterine Morcellation Within a Specimen Containment System: A Study of Bag Integrity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26663999" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Laparoscopic Morcellation of Fibroid and Uterus In-Bag.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27107329" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Single-site in-bag morcellation achieved via direct puncture of the pneumoperitoneum cap, a cordless electric morcellator, and a 5-mm flexible scope.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27192613" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Power morcellation inside a secure endobag: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27194256" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Preclinical safety testing for morcellation and extraction for an endobag with sealable ports: in vitro pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32374421" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : In-bag manual versus uncontained power morcellation for laparoscopic myomectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27058770" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Extracorporeal Manual Morcellation of Very Large Uteri Within an Enclosed Endoscopic Bag: Our 5-Year Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27058770" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Extracorporeal Manual Morcellation of Very Large Uteri Within an Enclosed Endoscopic Bag: Our 5-Year Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27058770" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Extracorporeal Manual Morcellation of Very Large Uteri Within an Enclosed Endoscopic Bag: Our 5-Year Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22634019" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Vaginal morcellation: a new strategy for large gynecological malignant tumor extraction: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22811899" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A Novel Technique for Transvaginal Retrieval of Enlarged Pelvic Viscera during Minimally Invasive Surgery.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
